Background: The identification of oncogene addicted NSCLC and the development of target therapies lead to improvement in survival rates and quality of life. In addition to other drugable targets such as EGFR mutation and ALK translocation, RET fusion has been shown to be an oncogenic driver in 1 to 2% of patients with NSCLC. Method: Here we report a 23-year old never-smoker male patient (Pt) diagnosed with lung adenocarcinoma, metastatic to lymph nodes, bones and lungs. Tumor biopsy was performed during broncoscopy. Tissue molecular testing was negative for EGFR (cobas) and ALK (FISH), and PDL-1 tumor proportional score (22C3) was 5%. Pt presented rapid disease progression after one cycle of cisplatin and pemetrexed, with pleural effusion and respiratory distress. Since initial tissue biopsy paraffin had been exhausted, next generation sequencing in cell-free tumor circulating DNA in plasma was performed (Guardant360). CCDC6-RET fusion and TP53 mutation (T256I) were identified. Result: Based on promising activity of the combination of VAN with EVE previously reported, and the lack of clinical trials in this setting in Brazil, Pt started oral target therapy with VAN 300 mg and EVE 10 mg daily. He had unequivocal clinical improvement over the following weeks, with discontinuation of pain medications and relief of respiratory symptoms. After 30 days on treatment, restaging CT scans demonstrated a dramatic response. Adverse events were grade (G) 1 cutaneous rash, G1 stomatitis and G1 diarrhoea. Pt also presented G1 pneumonitis that resolved rapidly with EVE temporary discontinuation. He remained without disease progression at 4+ months. After 5 months, he presented pneumonitis recurrence with respiratory failure. VAN is a multitargeted tyrosine kinase inhibitor of EGFR, VEGFR and RET, with limited activity in RET-rearranged NSCLC phase 2 trial. However, the concurrent inhibition of RET and the mammalian target of rapamycin (mTOR) has shown promising activity for RET-rearranged tumors in preclinical models. Among the 6 evaluable NSCLC patients with RET fusions treated with VAN and EVE in phase I trial, 5 achieved partial responses (83%) and 1 stable disease (16%). In particular, it has been suggested that CCDC6-RET subtype shows higher sensitivity to VAN. Conclusion: This case report corroborates the promising activity of combination of VAN and EVE in RET-rearranged NSCLC. 
P3.13-34 RET Gene, a New Choice for NSCLC Y. Wang, K. Ma, Y. Xu The First Bethune Hospital of Jilin University, Changchun/CN Background: RET gene, accounting for 1-2% of non-small cell lung cancer (NSCLC), has been identified as a novel target molecule which has been reported that could not coexist with other gene mutations such as rejected with the other mutation like KRAS, EGFR, BRAF, MEK1, HER2 and ALK. The emerging targeted agents Cabozantinib and Vandetanib have been recommended by NCCN guidelines for non-small cell lung cancer with RET fusion, based on a series of clinical trials. Method: We presented a case of lung adenocarcinoma with KIF5B/RET fusion. The patient was a 50-year-old, male, non-smoker, diagnosed as left upper lobe adenocarcinoma lung cancer. We performed a radical resection of pulmonary carcinoma for two years ago. Subsequently, he completed four cycles of chemotherapy with gemcitabine and cisplatin.
However, half years later, pleural metastasis made him have to receive systemic treatment but no chemotherapy due to his worse tolerance. We then performed a gene examination with the PCR method using the intraoperative specimen, and finally found positive KIF5B/RET fusion gene. From then on June 10,2017, he started to take cabozantinib for treatment. Result: He started to take cabozantinib (140 mg orally, once daily) for about nine months. His disease sustained SD during that period (please see Figure 1 ). No serious adverse events (AEs) except rash (Ⅱ grade) occurred in the whole treatment process. Conclusion:
We found that the RET gene is a new alternative for lung adenocarcinoma patients without common mutations such as EGFR, ALK, ROS1 and so on. This case report supports a useful reference for the therapy of lung adenocarcinoma patients with RET mutation and may provide a new choice for this kind of NSCLC patients. Keywords: RET gene mutation, cabozantinib, Targeted therapy P3.13-35 Antitumor Effect of Neratinib Targeting HER2-Altered Lung Cancer Y. Ogoshi Okayama University Graduate School of Medicine, Okayama/JP Background: Human epidermal growth factor receptor 2 (HER2) plays an important role in the pathogenesis of various cancers. HER2 alterations have been suggested to be a therapeutic target in non-small-cell lung cancer (NSCLC), as in breast and gastric cancers. However, the benefit of HER2-targeted therapy is much less defined. The aim of the study is to investigate the antitumor effect of neratinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), in NSCLC cells harboring HER2 alterations. Method: We examined the sensitivity of neratinib against normal bronchial epithelial cells BEAS-2B which ectopically overexpressing wild-type or mutant HER2. Human cDNAs encoding full-length HER2 (wild-type and its variants A775insYVMA, G776VC, G776LC, P780insGSP, V659E, G660D, and S310F) were inserted into the pIDT-SMART (C-TSC) vector, pCMViRTSC. Furthermore, we examined the antitumor activity of neratinib in several NSCLC cell lines harboring HER2 alterations in vitro and in vivo experiments, and investigated the association between their genetic alterations and sensitivity to neratinib treatment. Result: BEAS-2B cells ectopically overexpressing wild-type HER2 or mutants (A775insYVMA, G776VC, G776LC, P780insGSP, V659E, G660D, and S310F) showed constitutive auto phosphorylation of HER2 and activation of downstream signaling by Western blotting. These BEAS-2B cells were sensitive to neratinib, but insensitive to erlotinib, a first generation EGFR-TKI. Neratinib significantly inhibited the growth of HER2-altered (H2170, Calu-3, and H1781) NSCLC cell lines with an average IC 50 value of 0.00347mL, 0.0428mL, and 0.0119mL. Neratinib administration showed strong antitumor effect on tumor growth in mouse xenograft model using HER2-altered lung cancer cell lines. Conclusion: Our study strongly suggests that neratinib is a promising therapeutic option for the treatment of HER2-altered NSCLC. Background: Pulmonary metastases are a common site of spread for many cancers. We describe the long-term outcomes of surgical resection of pulmonary metastases at two major cancer centres. Method:
The study institutions thoracic surgery databases were searched for all
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